The Biosimilars Quiz Game: Evaluating the Role of Biosimilars in the Management of Rheumatologic Conditions

Watch our recent quiz game on biosimilars in rheumatologic conditions.
Stanley B. Cohen, MD
Jonathan Kay, MD
Kenneth G. Saag, MD, MSc
Released: November 28, 2017 Expiration: No longer available for credit

Related Content

CCO slides: current best practice for choosing among biologics and other JAK inhibitors for patients with moderate to severe ulcerative colitis

Released: November 13, 2020

Expert video from Clinical Care Options (CCO) on optimal management of inflammatory bowel disease (IBD), including ulcerative colitis, Crohn disease

Uma Mahadevan, MD William Sandborn, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Released: November 13, 2020 Expired: November 12, 2021

Pooled analysis of filgotinib trials in rheumatoid arthritis presented at ACR 2020 finds low incidence of VTE and MACE regardless of dose, by CCO

Released: November 13, 2020
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by independent educational grants from
Boehringer Ingelheim Pharmaceuticals, Inc.
Sandoz Inc., a Novartis Division

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue